Dermapharm Holding SE (DMP) Valuation & Financial Model
Interactive Discounted Cash Flow (DCF) model for Dermapharm Holding SE (XETRA:DMP), currently being evaluated. In 2025, Dermapharm Holding SE generated $1.16 Billion in revenue and $139.39 Million in free cash flow. Explore projected intrinsic value assumptions based on institutional-grade macro metrics.
Valuation Methodology & Recent Performance
The financial model for Dermapharm Holding SE is calculated using an institutional discounted cash flow (DCF) engine utilizing recent operational metrics:
- Current Price: N/A
- Recent Revenue (2025): $1.16 Billion
- Free Cash Flow (2025): $139.39 Million
- Discount Rate (WACC): Derived using the Risk-Free Rate (e.g., 10Y Gov Bond) plus an Equity Risk Premium based on market volatility and stock price variance.
- Terminal Value: Projected using a perpetual growth model bounded by long-term macroeconomic estimates.